No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HUMA240517P7500
- 2.10
- -1.90-47.50%
15min DelayClose May 13 16:00 ET
2.10High2.05Low
2.05Open4.00Pre Close4 Volume18 Open Interest7.50Strike Price830.00Turnover299.54%IV-2.83%PremiumMay 17, 2024Expiry Date2.02Intrinsic Value100Multiplier3DDays to Expiry0.08Time Value100Contract SizeAmericanOptions Type-0.8056Delta0.1631Gamma2.52Leverage Ratio-0.0587Theta-0.0006Rho-2.03Eff Leverage0.0016Vega
Intraday
- 5D
- 1D
News
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)
Express News | Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 215.79% Benchmark → $15 Reiterates Buy → Buy 04/01/2024 47.37% Cantor Fitzgerald → $7 Reiterate
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Humacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Comments
$Humacyte(HUMA.US$ Senator Tommy Tuberville filed 8 security purchases, including small biotech company Humacyte (HUMA) which has been testing to repair injuries in Ukraine.
1
2
$Humacyte(HUMA.US$ Humacyte Announces FDA Has Accepted And Granted For Priority Review The Company's Biologics License Application Seeking Approval Of Human Acellular Vessel
Read more
Dream is Possible : What would have happened if Ukraine surrendered ealier